The most recent Covid-19 variant Omicron is a stark reminder that the threat posed by the next global virus presents a clear national security risk to the American people that should sharpen our collective focus on the strategic import of investing in biopharmaceutical therapeutics and vaccines.
Our Biopharma Industry Is A Critical National Security Asset, And Disarming It Before The Next Pandemic Is Folly
